» Articles » PMID: 29922517

Transcriptional Regulation of Metabolism in Disease: From Transcription Factors to Epigenetics

Overview
Journal PeerJ
Date 2018 Jun 21
PMID 29922517
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Every cell in an individual has largely the same genomic sequence and yet cells in different tissues can present widely different phenotypes. This variation arises because each cell expresses a specific subset of genomic instructions. Control over which instructions, or genes, are expressed is largely controlled by transcriptional regulatory pathways. Each cell must assimilate a huge amount of environmental input, and thus it is of no surprise that transcription is regulated by many intertwining mechanisms. This large regulatory landscape means there are ample possibilities for problems to arise, which in a medical context means the development of disease states. Metabolism within the cell, and more broadly, affects and is affected by transcriptional regulation. Metabolism can therefore contribute to improper transcriptional programming, or pathogenic metabolism can be the result of transcriptional dysregulation. Here, we discuss the established and emerging mechanisms for controling transcription and how they affect metabolism in the context of pathogenesis. Cis- and trans-regulatory elements, microRNA and epigenetic mechanisms such as DNA and histone methylation, all have input into what genes are transcribed. Each has also been implicated in diseases such as metabolic syndrome, various forms of diabetes, and cancer. In this review, we discuss the current understanding of these areas and highlight some natural models that may inspire future therapeutics.

Citing Articles

Regulatory networks driving expression of genes critical for glioblastoma are controlled by the transcription factor c-Jun and the pre-existing epigenetic modifications.

Roura A, Szadkowska P, Poleszak K, Dabrowski M, Ellert-Miklaszewska A, Wojnicki K Clin Epigenetics. 2023; 15(1):29.

PMID: 36850002 PMC: 9972689. DOI: 10.1186/s13148-023-01446-4.


Transcription Factors in Cancer Development and Therapy.

Vishnoi K, Viswakarma N, Rana A, Rana B Cancers (Basel). 2020; 12(8).

PMID: 32824207 PMC: 7464564. DOI: 10.3390/cancers12082296.


Metabolic Dysregulation Controls Endocrine Therapy-Resistant Cancer Recurrence and Metastasis.

Blundon M, Dasgupta S Endocrinology. 2019; 160(8):1811-1820.

PMID: 31157867 PMC: 6620757. DOI: 10.1210/en.2019-00097.

References
1.
Jo S, Kim D, Clocchiatti A, Dotto G . PDCD4 is a CSL associated protein with a transcription repressive function in cancer associated fibroblast activation. Oncotarget. 2016; 7(37):58717-58727. PMC: 5312270. DOI: 10.18632/oncotarget.11227. View

2.
Pfarr N, Szamalek-Hoegel J, Fischer C, Hinderhofer K, Nagel C, Ehlken N . Hemodynamic and clinical onset in patients with hereditary pulmonary arterial hypertension and BMPR2 mutations. Respir Res. 2011; 12:99. PMC: 3163544. DOI: 10.1186/1465-9921-12-99. View

3.
Li M, Li J, Ding X, He M, Cheng S . microRNA and cancer. AAPS J. 2010; 12(3):309-17. PMC: 2895440. DOI: 10.1208/s12248-010-9194-0. View

4.
He L, Hannon G . MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004; 5(7):522-31. DOI: 10.1038/nrg1379. View

5.
Summermatter S, Shui G, Maag D, Santos G, Wenk M, Handschin C . PGC-1α improves glucose homeostasis in skeletal muscle in an activity-dependent manner. Diabetes. 2012; 62(1):85-95. PMC: 3526021. DOI: 10.2337/db12-0291. View